-
Oct.112022NEWS
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Devel..
-
Oct.112022NOTICE
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in..
-
Oct.052022NEWS
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partn..
-
Jul.292022NEWS
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
-
Apr.282022NEWS
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update
-
Apr.112022NEWS
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiat..